Navigation Links
Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Date:4/30/2008

here is currently no FDA-approved therapy for treating cancer cachexia.

VT-122 is an oral, multi-targeted, chrono-modulated, fixed dose combination of propranolol and etodolac. Vicus chose the constituent drugs based on the results of its cancer cachexia disease model that predicted blocking systemic inflammation would reverse the wasting process. The use of this combination was initially assessed in investigator-led pilot trials. Data obtained from a total of nine evaluable subjects demonstrated reversal of rapid weight loss in seven subjects. No treatment related serious adverse events were reported.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held biopharmaceutical company focused on developing oncology supportive care drug products for serious unmet medical needs. These products include: VT-122, in Phase 2 clinical trials, for cancer cachexia; VT-211 and VT-212, in investigator-led pilot trials, for chemotherapy-induced oral mucositis and neutropenia; and VT-310, in pre-clinical evaluation, for cancer-related fatigue. Each product candidate is a novel combination and dosing regimen of two generic drugs with known safety profiles. The constituent drugs and dosing regimens are chosen based on the results of Vicus' predictive disease models and the company's understanding of the body's maladaptive response to cancer and its treatment.

Website: http://www.vicustherapeutics.com


'/>"/>
SOURCE Vicus Therapeutics, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
3. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
4. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
5. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
6. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
7. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
8. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
9. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
10. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
11. Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Roxane Laboratories, Inc. announced today the approval of its Abbreviated ... by the U.S. Food and Drug Administration. The product is available ... nationwide. , , , ... Laboratories, Naratriptan Tablets USP are AB rated to AMERGE® (naratriptan hydrochloride) ...
... SPRING, Md. , July 8 People who use the malaria drug Qualaquin to treat ... , , ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) , ... and Drug Administration (FDA) says they may be at risk for serious and life-threatening effects. , ...
Cached Medicine Technology:Roxane Laboratories, Inc. Announces the Launch of Naratriptan Tablets USP 2FDA Consumer Health Information: Using Malaria Medication For Leg Cramps Is Risky 2
(Date:12/24/2014)... 24, 2014 The Healthy Home Company has ... raise families. In-Vest USA is dedicated to ... – our first responders. Today, these two organizations have joined ... providing them with body armor through In-Vest’s USA’s Bless the ... that happened this past week in New York. ...
(Date:12/24/2014)... There’s a lot going on with The Affordable Care ... control of the Senate as well as the House, a ... lawsuit has been brought against President Obama by the House, ... have resulted in changes to the law without the approval ... place to weigh the validity of subsidies provided to low ...
(Date:12/24/2014)... “ Relax Melodies ” was featured on NewsWatch ... latest and coolest mobile applications on the iOS, Android, ... and host of NewsWatch, conducted the app review and ... they can fall asleep. , According to the National ... some sort of difficulty sleeping. Since that’s a huge ...
(Date:12/24/2014)... 2014 Dr. Ronald Receveur, a ... placing dental implants in a day, has ... of overusing teeth-whitening treatments. , In his blog ... Dr. Receveur writes that overusing teeth-whitening treatments can lead ... to enamel. , “Because teeth-whitening treatments are ...
(Date:12/24/2014)... year, more than one-third of the more than 10,000 ... extreme heat conditions, according to recent federal statistics. ... the leading cause of heat-related illness among Americans, but ... infections, also put older people at higher risk for ... help health care systems anticipate and perhaps prevent many ...
Breaking Medicine News(10 mins):Health News:The Healthy Home Company and In-Vest USA Team Up to Save the Lives of Law Enforcement 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:An Application to Help with Insomnia was Featured on NewsWatch Television on December 19, 2014 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 2Health News:New Albany Dentist Weighs In On New Trend of Overbleaching Teeth 3Health News:Heat Stroke, Kidney Failure Help Drive Illnesses From Extreme Heat 2
... Key New Products Including Completing CE Mark, ... -, TSX Venture Exchange: NVC,VANCOUVER, April ... that it has completed a previously announced non-brokered private ... of $0.21 per unit for aggregate gross proceeds of ...
... Copenhagen, Denmark, Friday 24 April: HIV positive and ... transplant, according to new research presented today at EASL ... the Study of Liver in Copenhagen, Denmark. , The ... 1 and 5 years between HIV negative and HIV ...
... highest standards in the security industry , ... Freeport, ... Inc. is pleased to announce it has once again been awarded ... Alarm Association (CSAA)., , , , ,There are approximately 2,700 central ...
... community and helps individuals with vision care and restoration. , ... ... Christian is an affluent, prestigious, private high school, nestled in the ... their efforts and dedication toward educating America,s youth, by donating several ...
... much as younger ones, , , THURSDAY, April 23 (HealthDay ... older than 50 -- even if they,ve had several ... level of risk as younger women, European researchers contend. ... repeating smear tests in women 60 to 65 years ...
... MINNEAPOLIS, April 23 As federal policymakers pursue healthcare ... health promotion and disease prevention will be critically evaluated. ... more than 40 of North America,s top medical schools ... original scientific research in the area of integrative medicine. ...
Cached Medicine News:Health News:Neovasc Completes $2 Million Non-Brokered Private Placement 2Health News:Neovasc Completes $2 Million Non-Brokered Private Placement 3Health News:HIV positive and HIV negative patients have similar survival rates following liver transplant 2Health News:New York Merchants Protective Co. Renews CSAA Five Diamond Certification 2Health News:New York Merchants Protective Co. Renews CSAA Five Diamond Certification 3Health News:Khanna Institute Supports Oaks Christian School's Annual Fundraiser 2Health News:Don't Lower Age for Cervical Cancer Test, Study Urges 2Health News:Advancements in Integrative Medicine Research to Be Evaluated by Scientists From Leading International Academic Health Centers 2
The CGIL iridectomy contact glass was designed by Riquin, Fankhauser et al. to perform full thickness peripheral laser iridectomies....
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... uses a classical distance-independent measuring principle which ... The size of the mire image is ... and the measured object; 2. The resulting ... the Ophthalmometer and the measured object; 3. ...
Medicine Products: